15 results about "APPETITE SUPPRESSANTS" patented technology

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

To provide anti-obesity agents to overcome defects of currently used anti-obesity agents, that is, as main types of the previously developed anti-obesity drugs, appetite suppressants acting on the central nervous system are drugs that control the action of neurotransmitters (for example, phentermine, mazindol, lorcaserin, fluoxetine and sibutramine) were mostly used, but the neurotransmitter modulators exert a wide range of effects on various physiological actions in addition to appetite suppression by numerous subtype receptors, so that the modulators are lacking in selectivity for each subtype and have a large disadvantage in that various side effects are accompanied in a case of long-term administration.SOLUTION: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.SELECTED DRAWING: None

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

N-Lactoyl-Phenylalanine (Lac-Phe) analogues are disclosed having activity as appetite suppressants useful as therapeutics in the treatment of obesity and related secondary diseases. Methods of synthesis of the N-Lactoyl-Phenylalanine (Lac-Phe) analogues are also disclosed, as well as methods of use and treatment with the Lac-Phe analogues.

The present invention provides a method for preparing a plasticized superporous hydrogel material, which comprises subjecting an initial hydrogel material to treatment with an acidic solution, optionally treatment with a monovalent metal salt solution, freeze-drying and plasticization. Optionally, the method of the present invention prepares a molded plasticized superporous hydrogel material body in which one or more through-holes are formed. The plasticized superporous hydrogel material of the present invention can be formulated into a suitable oral dosage form for appetite suppressants and for delivering drugs and / or nutraceuticals to a human or animal body.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present invention aims to provide a food (including foods for specified health uses and foods with functional claims) or pharmaceutical product containing rare sugars as an active ingredient that can be used for novel applications. [Solution] The above problem is achieved by a food composition or pharmaceutical composition containing D-allose, D-sorbose, or derivatives thereof as an active ingredient, for the prevention, improvement, or treatment of symptoms or diseases selected from the group consisting of obesity due to overeating, diabetes or elevated blood glucose levels resulting from obesity due to overeating, and hepatic fat accumulation resulting from obesity due to overeating.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.